Skip to content

Nektar Therapeutics NKTR Net gains (losses) on investments

Net gains (losses) on investments at other companies

Amgen logo
AmgenAMGN
-$143M-111%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$180K-1,536%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$85K-22.7%
Incyte logo
IncyteINCY
$6.59M+591%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's net gains (losses) on investments?
Nektar Therapeutics (NKTR) reported net gains (losses) on investments of -$1.75M in Q1 2026.
How has Nektar Therapeutics's net gains (losses) on investments changed year-over-year?
Nektar Therapeutics's net gains (losses) on investments increased by 60.8% year-over-year, from -$4.46M to -$1.75M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.